449 related articles for article (PubMed ID: 18817633)
21. Comparative molecular dynamics simulations of HIV-1 integrase and the T66I/M154I mutant: binding modes and drug resistance to a diketo acid inhibitor.
Brigo A; Lee KW; Fogolari F; Mustata GI; Briggs JM
Proteins; 2005 Jun; 59(4):723-41. PubMed ID: 15815973
[TBL] [Abstract][Full Text] [Related]
22. Pharmacophore-based design of HIV-1 integrase strand-transfer inhibitors.
Barreca ML; Ferro S; Rao A; De Luca L; Zappalà M; Monforte AM; Debyser Z; Witvrouw M; Chimirri A
J Med Chem; 2005 Nov; 48(22):7084-8. PubMed ID: 16250669
[TBL] [Abstract][Full Text] [Related]
23. Dissecting Tn5 transposition using HIV-1 integrase diketoacid inhibitors.
Czyz A; Stillmock KA; Hazuda DJ; Reznikoff WS
Biochemistry; 2007 Sep; 46(38):10776-89. PubMed ID: 17725323
[TBL] [Abstract][Full Text] [Related]
24. Docking dinucleotides to HIV-1 integrase carboxyl-terminal domain to find possible DNA binding sites.
Zhu HM; Chen WZ; Wang CX
Bioorg Med Chem Lett; 2005 Jan; 15(2):475-7. PubMed ID: 15603976
[TBL] [Abstract][Full Text] [Related]
25. Mining the NCI antiviral compounds for HIV-1 integrase inhibitors.
Deng J; Kelley JA; Barchi JJ; Sanchez T; Dayam R; Pommier Y; Neamati N
Bioorg Med Chem; 2006 Jun; 14(11):3785-92. PubMed ID: 16460953
[TBL] [Abstract][Full Text] [Related]
26. Correlation of biological activity with active site binding modes of geminal disulfone HIV-1 integrase inhibitors.
Meadows DC; Tantillo DJ; Gervay-Hague J
ChemMedChem; 2006 Sep; 1(9):959-64. PubMed ID: 16952140
[No Abstract] [Full Text] [Related]
27. Tn5 transposase as a useful platform to simulate HIV-1 integrase inhibitor binding mode.
Barreca ML; Ortuso F; Iraci N; De Luca L; Alcaro S; Chimirri A
Biochem Biophys Res Commun; 2007 Nov; 363(3):554-60. PubMed ID: 17889829
[TBL] [Abstract][Full Text] [Related]
28. Structure-activity relationships: analogues of the dicaffeoylquinic and dicaffeoyltartaric acids as potent inhibitors of human immunodeficiency virus type 1 integrase and replication.
King PJ; Ma G; Miao W; Jia Q; McDougall BR; Reinecke MG; Cornell C; Kuan J; Kim TR; Robinson WE
J Med Chem; 1999 Feb; 42(3):497-509. PubMed ID: 9986720
[TBL] [Abstract][Full Text] [Related]
29. Modeling, analysis, and validation of a novel HIV integrase structure provide insights into the binding modes of potent integrase inhibitors.
Chen X; Tsiang M; Yu F; Hung M; Jones GS; Zeynalzadegan A; Qi X; Jin H; Kim CU; Swaminathan S; Chen JM
J Mol Biol; 2008 Jul; 380(3):504-19. PubMed ID: 18565342
[TBL] [Abstract][Full Text] [Related]
30. HIV type 1 integrase inhibitors: from basic research to clinical implications.
Jegede O; Babu J; Di Santo R; McColl DJ; Weber J; Quiñones-Mateu M
AIDS Rev; 2008; 10(3):172-89. PubMed ID: 18820719
[TBL] [Abstract][Full Text] [Related]
31. Crystal structure of the HIV-1 integrase core domain in complex with sucrose reveals details of an allosteric inhibitory binding site.
Wielens J; Headey SJ; Jeevarajah D; Rhodes DI; Deadman J; Chalmers DK; Scanlon MJ; Parker MW
FEBS Lett; 2010 Apr; 584(8):1455-62. PubMed ID: 20227411
[TBL] [Abstract][Full Text] [Related]
32. HIV integrase as a target for antiviral chemotherapy.
Nair V
Rev Med Virol; 2002; 12(3):179-93. PubMed ID: 11987143
[TBL] [Abstract][Full Text] [Related]
33. Rational design of 2-pyrrolinones as inhibitors of HIV-1 integrase.
Ma K; Wang P; Fu W; Wan X; Zhou L; Chu Y; Ye D
Bioorg Med Chem Lett; 2011 Nov; 21(22):6724-7. PubMed ID: 21996518
[TBL] [Abstract][Full Text] [Related]
34. Synthesis and biological evaluation of geminal disulfones as HIV-1 integrase inhibitors.
Meadows DC; Mathews TB; North TW; Hadd MJ; Kuo CL; Neamati N; Gervay-Hague J
J Med Chem; 2005 Jul; 48(14):4526-34. PubMed ID: 15999991
[TBL] [Abstract][Full Text] [Related]
35. Curcumin analogs with altered potencies against HIV-1 integrase as probes for biochemical mechanisms of drug action.
Mazumder A; Neamati N; Sunder S; Schulz J; Pertz H; Eich E; Pommier Y
J Med Chem; 1997 Sep; 40(19):3057-63. PubMed ID: 9301668
[TBL] [Abstract][Full Text] [Related]
36. Synthesis and biological evaluation of 5-fluoroquinolone-3-carboxylic acids as potential HIV-1 integrase inhibitors.
He QQ; Zhang X; Yang LM; Zheng YT; Chen F
J Enzyme Inhib Med Chem; 2013 Aug; 28(4):671-6. PubMed ID: 22468749
[TBL] [Abstract][Full Text] [Related]
37. Diketo acid inhibitor mechanism and HIV-1 integrase: implications for metal binding in the active site of phosphotransferase enzymes.
Grobler JA; Stillmock K; Hu B; Witmer M; Felock P; Espeseth AS; Wolfe A; Egbertson M; Bourgeois M; Melamed J; Wai JS; Young S; Vacca J; Hazuda DJ
Proc Natl Acad Sci U S A; 2002 May; 99(10):6661-6. PubMed ID: 11997448
[TBL] [Abstract][Full Text] [Related]
38. A versatile and practical synthesis toward the development of novel HIV-1 integrase inhibitors.
Rinaldi M; Tintori C; Franchi L; Vignaroli G; Innitzer A; Massa S; Esté JA; Gonzalo E; Christ F; Debyser Z; Botta M
ChemMedChem; 2011 Feb; 6(2):343-52. PubMed ID: 21246739
[TBL] [Abstract][Full Text] [Related]
39. Design and synthesis of caffeoyl-anilides as portmanteau inhibitors of HIV-1 integrase and CCR5.
Bodiwala HS; Sabde S; Gupta P; Mukherjee R; Kumar R; Garg P; Bhutani KK; Mitra D; Singh IP
Bioorg Med Chem; 2011 Feb; 19(3):1256-63. PubMed ID: 21227704
[TBL] [Abstract][Full Text] [Related]
40. Analysis of binding parameters of HIV-1 integrase inhibitors: correlates of drug inhibition and resistance.
Loizidou EZ; Zeinalipour-Yazdi CD; Christofides T; Kostrikis LG
Bioorg Med Chem; 2009 Jul; 17(13):4806-18. PubMed ID: 19450984
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
